1stOncology™: Cancer Intelligence Service – Page 8762 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress

On September 12, 2021 MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, reported poster presentations relating to multiple investigational product candidates at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Virtual Conference, taking place September 16-21, 2021 (Press release, MacroGenics, SEP 12, 2021, View Source [SID1234587532]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Posters will be available on September 16, 2021. Details are as follows:

620P – MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in Patients with Advanced Solid Tumors: Preliminary Results of Phase 1 Cohort Expansion
Preliminary clinical results from the Phase 1 cohort expansion study of MGC018 in patients with metastatic castration-resistant prostate cancer and non-small cell lung cancer will be presented in this poster. The abstract submitted to ESMO (Free ESMO Whitepaper) included data as of May 3, 2021, while the final poster will include updated results as of August 16, 2021.
Presentation Topic: Genitourinary tumours, prostate

1379P – Margetuximab with Retifanlimab in HER2+, PD-L1+ First-Line Unresectable/Metastatic Gastroesophageal Adenocarcinoma (GEA): MAHOGANY Cohort A
Results from Cohort A Part 1 of the Phase 2/3 MAHOGANY clinical trial of margetuximab in combination with retifanlimab in treatment-naïve patients with locally advanced or metastatic gastroesophageal adenocarcinoma (GEA) who are positive for both HER2 and PD-L1 will be presented in this poster. The efficacy data and safety cutoff dates for this poster were July 19, 2021 and August 3, 2021, respectively.
Presentation Topic: Oesophagogastric cancer

627P – Phase 2 Neoadjuvant Trial of the Anti-B7-H3 Antibody, Enoblituzumab, in Men with Localized Prostate Cancer: Safety, Efficacy, and Immune Correlates
Results of a Phase 2 neoadjuvant trial of enoblituzumab in men with localized prostate cancer will be presented in this poster by Johns Hopkins University School of Medicine.
Presentation Topic: Genitourinary tumours, prostate

926TiP – Phase 2 Trial of Enoblituzumab Plus Retifanlimab or Tebotelimab in First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
A trial-in-progress poster regarding the Phase 2 study of enoblituzumab, an Fc‐engineered, anti‐B7‐H3 monoclonal antibody, will be presented.
Presentation Topic: Head and neck cancer, excluding thyroid

The abstracts referenced above were submitted to ESMO (Free ESMO Whitepaper) in May 2021 and are available on the ESMO (Free ESMO Whitepaper) website. The posters will be available for on-demand viewing on the ESMO (Free ESMO Whitepaper) website and on the "Events & Presentations" page in the Investor Relations section of MacroGenics’ website at View Source on or around September 16, 2021.

Immunocore to present at upcoming investor conferences

On September 10, 2021 Immunocore Holdings plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, reported that management will present at the following investor conferences in September (Press release, Immunocore, SEP 10, 2021, View Source [SID1234590901]).

H.C. Wainwright 23rd Annual Global Investment Conference
Fireside Chat available on demand starting at 7:00 a.m. ET on Monday, September 13, 2021
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Fireside Chat: Wednesday, September 22, 2021 at 2:05 p.m. ET
The investor conferences will each be held in a virtual format and a live webcast of each presentation can be accessed in the ‘Investors’ section of Immunocore’s website at www.immunocore.com. For conferences that offer replays, presentations will be made available for a limited time.

September 10, 2021 – T-CURE BIOSCIENCE ANNOUNCED PRESENTATIONS AT THREE UPCOMING HEALTHCARE CONFERENCES

On September 10, 2021 T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, reported that the management will present virtually at the following upcoming healthcare conferences (Press release, T-Cure Bioscience, SEP 10, 2021, View Source [SID1234590211]):

5th Annual Cell Gene Therapy World Asia 2021, Singapore

Gang Zeng, Ph.D., Chief Executive Officer, will present virtually on Wednesday, September 16, 2021, at 11:30 am. (Singapore Time). The title of his presentation is "Targeting Solid Tumors with Novel TCR-T Strategies"
2021 Baird Global Healthcare Conference

Erika von Euw, Ph.D. Senior Director of Translational Research, and Gang Zeng, Ph.D. will give a presentation on T-Cure Bioscience on Wednesday, September 15, at 3:10 p.m. (EDT).
2021 Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Erika von Euw, PhD, and Gang Zeng, Ph.D. will give a presentation on T-Cure Bioscience on Thursday, September 23, at 12:25 pm (EDT).

APOLLOMICS, INC. DOSES FIRST PATIENT IN A PHASE I CLINICAL TRIAL OF APL-102

On September 10, 2021 Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, reported the successful dosing of the first patient in a Phase I clinical study of APL-102 in patients with advanced solid tumors (Press release, Apollomics, SEP 10, 2021, View Source [SID1234587921]). The Phase I trial is designed to assess the safety, tolerability and pharmacokinetics of APL-102 delivered via an oral capsule.

"APL-102 is an internally discovered and developed tyrosine kinase inhibitor targeting multiple oncogenic drivers, and we are excited about advancing it for clinical testing to explore its potential for treating a number of solid tumors;" said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. "APL-102 is the first of several novel assets planned for clinical development to further expand Apollomics’ clinical pipeline in oncology."

About APL-102

APL-102 is an oral, small molecule multi kinase inhibitor (MTKi) targeting several key oncogenic drivers. APL-102 inhibits several receptor tyrosine kinases (RTKs), including: angiogenesis via vascular endothelial growth factor receptors (VEGFRs), mitogen-activated protein kinase (MAPK) pathway via B-RAF and C-RAF; and colony stimulating factor 1 receptor (CSF1R).

Preclinical studies have demonstrated broad and potent antitumor activity in patient-derived xenograft mouse models of liver, breast, colorectal, gastric, esophageal and lung cancers. APL-102 has also shown favorable preclinical pharmacokinetic (PK) and safety profiles with no serious off-target activity observed. APL-102 has the potential to be used as a single agent or in combination with other oncology agents.

Apollomics retains worldwide rights to APL-102.

Senhwa Announces First Patient Successfully Dosed in Phase 1b Expansion Study of Pidnarulex to Treat Solid Tumors with Specific Homologous Recombination Gene Mutations

On September 10, 2021 Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, reported that their first patient has been successfully dosed, in a Phase 1b clinical study of Pidnarulex as a potential treatment for solid tumors with Homologous Recombination (HR) gene mutations, at the Princess Margaret Cancer Centre in Toronto, Canada (Press release, Senhwa Biosciences, SEP 10, 2021, View Source [SID1234587877]).

This new Phase 1b open-label, multi-center Expansion study (in both US and Canada) was designed to determine a tolerable dose of Pidnarulex in patients with selected solid tumors with BRCA1/2, PALB2, and other HR gene mutations. This dose will be used in future Phase II trials.

"We are very excited to begin enrollment in our Phase 1b clinical trial for evaluating Pidnarulex in patients with BRCA1/2, PALB2 and other homologous recombination gene mutations. This is an important milestone and marks a new paradigm in the treatment of cancers with specific pathogenic mutations," stated Dr. John Soong, Chief Medical Officer of Senhwa Biosciences.

In a previous Phase 1 trial, Pidnarulex demonstrated clinically significant and lasting benefits in patients with specific tumor biomarkers, such as BRCA1/2, and PALB2 mutations and that were also resistant to platinum and other chemotherapeutics. This past May, the American College of Medical Genetics and Genomics (ACMG) issued new guidance for patients and doctors, advising that individuals with PALB2 mutations be surveilled similarly to individuals with BRCA mutations. The experts have identified the PALB2 mutation as the third most important breast cancer gene after BRCA1 and BRCA2 mutations, as it also increases a patient’s risk of developing ovarian and pancreatic cancer.

"The new guidelines for the PALB2 mutation not only raises the public’s awareness and provides guidance regarding how to manage that risk, but also validates that our hard work is going in the right direction," said Tai-Sen Soong, Chief Executive Officer of Senhwa Biosciences.

While BRCA1/2 deficient tumor cells are more sensitive to PARP inhibitor (PARPi) treatments, PARPi resistance is not uncommon in clinical use. According to an article published on Molecular Cancer in 2020, more than 40% of BRCA1/2 deficient patients fail to respond to PARPi alone. By targeting the G-quadruplex DNA structure instead, Senhwa’s Pidnarulex also has great potential as an alternative treatment for patients who have developed resistance to PAPRi or other chemotherapies.